Public Company

Ranbaxy receives final USFDA approval for Glycopyrolate

Ranbaxy Laboratories today announced that it had received final approval from the US Food and Drug Administration (USFDA) to market and manufacture Glycopyrolate tablets. - India to export fresh litchi to US for first time - After mangoes, India to export litchis to US - Ranbaxy Labs launches protein supplement - Ranbaxy, Aurobindo get USFDA nod for migraine drug - Sun Pharma settles patent dispute with Astra Zeneca - Daiichi wins court battle against Mylan, Matrix The drug is indicated for use as adjunctive therapy in the treatment of peptic ulcer. The total annual market sales for Glycopyrolate was 426 million as of June 2009.

Add your comment:

Name:
Site address:	http://
Your message:
Enter today\\\\'s date, 2 digits (spam protection):